Verastem Inc. (VSTM)
| Bid | 5.48 |
| Market Cap | 246.79M |
| Revenue (ttm) | 11.18M |
| Net Income (ttm) | -103.32M |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -1.77 |
| Forward PE | -2.13 |
| Analyst | Buy |
| Ask | 5.75 |
| Volume | 442,909 |
| Avg. Volume (20D) | 1,305,117 |
| Open | 5.66 |
| Previous Close | 5.59 |
| Day's Range | 5.52 - 5.74 |
| 52-Week Range | 2.10 - 13.52 |
| Beta | 0.28 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel coho...
Analyst Forecast
According to 8 analyst ratings, the average rating for VSTM stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 116.41% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech ConferenceBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...
1 month ago · businesswire.com
Verastem Oncology Names Matthew E. Ros as Chief Operating OfficerBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appoi...
